<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS134146</article-id>
<article-id pub-id-type="doi">10.1101/2021.08.23.457378</article-id>
<article-id pub-id-type="archive">PPR387383</article-id>
<article-version article-version-type="publisher-id">2</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>SARS-CoV-2 infection induces soluble platelet activation markers and PAI-1 in the early moderate stage of COVID-19</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Al-Tamimi</surname>
<given-names>Abaher O.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yusuf</surname>
<given-names>Ayesha M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jayakumar</surname>
<given-names>Manju N.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ansari</surname>
<given-names>Abdul W.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Elhassan</surname>
<given-names>Mona</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>AbdulKarim</surname>
<given-names>Fatema</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kannan</surname>
<given-names>Meganathan</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Halwani</surname>
<given-names>Rabih</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ahmad</surname>
<given-names>Firdos</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="corresp" rid="CR1">#</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Cardiovascular Research Group, Sharjah Institute for Medical Research, University of Sharjah, Sharjah, 27272 UAE</aff>
<aff id="A2">
<label>2</label>Department of Internal Medicine, Rashid Hospital, Dubai, UAE</aff>
<aff id="A3">
<label>3</label>Blood and Vascular Biology Research Lab, Department of Life Sciences, Central University of Tamil Nadu, Thiruvarur, India</aff>
<aff id="A4">
<label>4</label>Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, 27272 UAE</aff>
<author-notes>
<corresp id="CR1">
<label>#</label>
<bold>Corresponding author</bold>: <bold>Firdos Ahmad, MSc, PhD</bold>, College of Medicine, University of Sharjah, Sharjah, UAE 27272, <email>fahmad@sharjah.ac.ae</email>, Ph; +971 6505 7752</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>08</day>
<month>09</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="preprint">
<day>23</day>
<month>08</month>
<year>2021</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://creativecommons.org/licenses/by-nd/4.0/</ali:license_ref>
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nd/4.0/">CC BY-ND 4.0 International license</ext-link>.</license-p>
</license>
<license>
<ali:license_ref>https://europepmc.org/downloads/openaccess</ali:license_ref>
<license-p>This preprint is made available via the <ext-link ext-link-type="uri" xlink:href="https://europepmc.org/downloads/openaccess">Europe PMC open access subset</ext-link>, for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original preprint source.</license-p>
</license>
</permissions>
<abstract>
<sec id="S1">
<title>Introduction</title>
<p id="P1">Coagulation dysfunction and thromboembolism emerge as strong comorbidity factors in severe COVID-19. However, it is unclear when particularly platelet activation markers and coagulation factors dysregulated during the pathogenesis of COVID-19. Here, we sought to assess the levels of coagulation and platelet activation markers at moderate and severe stages of COVID-19 to understand the pathogenesis.</p>
</sec>
<sec id="S2">
<title>Methods</title>
<p id="P2">To understand this, hospitalized COVID-19 patients with (severe cases that required intensive care) or without pneumonia (moderate cases) were recruited. Phenotypic and molecular characterizations were performed employing basic coagulation tests including PT, APTT, D-Dimer and TFPI. The flow cytometry-based multiplex assays were performed to assess FXI, anti-thrombin, prothrombin, fibrinogen, FXIII, P-selectin, sCD40L, plasminogen, tissue-plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) and D-Dimer.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P3">The investigations revealed induction of plasma P-selectin and CD40 ligand (sCD40L) in moderate COVID-19 cases which were significantly abolished with the progression of COVID-19 severity. Moreover, a profound reduction in plasma tissue factor pathway inhibitor (TFPI) and FXIII were identified particularly in the severe COVID-19. Further analysis revealed fibrinogen induction in both moderate and severe patients. Interestingly, an elevated PAI-1 more prominently in moderate, and tPA particularly in severe COVID-19 cases were observed. Particularly, the levels of fibrinogen and tPA directly correlated with the severity of the disease.</p>
</sec>
<sec id="S4">
<title>Conclusions</title>
<p id="P4">In summary, induction of soluble P-selectin, sCD40L, fibrinogen and PAI-1 in moderate COVID-19 cases suggests the activation of platelets and coagulation system before patients require intensive care. These findings would help in designing better thromboprophylaxis to limit the COVID-19 severity.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Coagulation</kwd>
<kwd>Platelet activation</kwd>
<kwd>FXIII</kwd>
<kwd>Embolism</kwd>
<kwd>TFPI</kwd>
<kwd>tPA</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="S5" sec-type="intro">
<title>Introduction</title>
<p id="P5">Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection often leads to respiratory conditions like acute respiratory distress syndrome (ARDS) and pneumonia in severe cases.<sup>
<xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R2">2</xref>
</sup> Preliminary cohort studies show a higher incidence of venous thromboembolic events in COVID-19 patients who particularly required intensive care.<sup>
<xref ref-type="bibr" rid="R3">3</xref>–<xref ref-type="bibr" rid="R4">4</xref>
</sup> Acute respiratory disease progression includes an early infection phase in which the virus attacks epithelial cells using angiotensin-converting enzyme 2 (ACE2) receptors, which leads to pneumonia and induction of severe systemic inflammation.<sup>
<xref ref-type="bibr" rid="R5">5</xref>
</sup> Coagulopathy is one of the most concerning features in severe COVID-19 patients which is characterized by prolonged prothrombin and activated partial thromboplastin times, elevated D-dimer, and fibrinogen levels.<sup>
<xref ref-type="bibr" rid="R6">6</xref>–<xref ref-type="bibr" rid="R7">7</xref>
</sup> The elevated coagulopathy markers are found to be associated with a higher mortality rate.<sup>
<xref ref-type="bibr" rid="R8">8</xref>–<xref ref-type="bibr" rid="R9">9</xref>
</sup>
</p>
<p id="P6">SARS-CoV-2 –induced endothelial damage releases a variety of soluble markers of endothelial dysfunction including von Willebrand factor (VWF), soluble E-selectin, P-selectin, thrombomodulin.<sup>
<xref ref-type="bibr" rid="R10">10</xref>–<xref ref-type="bibr" rid="R11">11</xref>
</sup> Such biologically active molecules eventually promote platelet activation. Platelet receptors regulate not only thrombosis but also initiate delayed cellular activities underlying inflammatory response against diverse pathogens, including viruses.<sup>
<xref ref-type="bibr" rid="R12">12</xref>
</sup> Tissue factor pathway inhibitor (TFPI) is a physiological inhibitor of TF and plays a critical role in balancing the initiation phase of coagulation. TFPI is a serine protease inhibitor that inhibits TF-FVIIa and prothrombinase complex (FXa/FVa) and regulates thrombin generation.<sup>
<xref ref-type="bibr" rid="R13">13</xref>–<xref ref-type="bibr" rid="R14">14</xref>
</sup>
</p>
<p id="P7">In a variety of infections, endothelial cells release proinflammatory cytokines such as TNF-α, IL-1, and IL-6 which in turn not only increases the expression of TF on the endothelial lining but also increases the plasminogen activator inhibitor-1 (PAI-1). Endotoxin-induced expression of TF and PAI-1 by endothelium thus may provide a stimulus that promotes thrombotic complication. <sup>
<xref ref-type="bibr" rid="R15">15</xref>–<xref ref-type="bibr" rid="R16">16</xref>
</sup> Several viral infections including dengue and influenza were found to be associated with platelet activation and inflammation through different molecular pathways.<sup>
<xref ref-type="bibr" rid="R17">17</xref>
</sup> The inflammatory reaction can also lead to a release of reactive oxygen species (ROS) and proteases which contribute to endothelial damage and further pathological remodeling of the venous wall.<sup>
<xref ref-type="bibr" rid="R18">18</xref>
</sup>
</p>
<p id="P8">Studies have revealed that patients infected with SARS-CoV-1 or MERS virus develop fibrin/thrombi within the pulmonary vasculature.<sup>
<xref ref-type="bibr" rid="R19">19</xref>
</sup> Studies with SARS-CoV-1 infected mice further suggest the abnormal expression of procoagulant genes such as thrombin, VII, XI, XII, and plasminogen activators especially in those who had fatal consequences.<sup>
<xref ref-type="bibr" rid="R20">20</xref>–<xref ref-type="bibr" rid="R21">21</xref>
</sup> Sepsis-induced coagulopathy (SIC) and disseminated intravascular coagulopathy (DIC) have been documented with severe disease, especially in non-survivors COVID-19 cases.<sup>
<xref ref-type="bibr" rid="R6">6</xref>
</sup> Though the dysregulation of plasma CD40 ligand (sCD40L)<sup>
<xref ref-type="bibr" rid="R22">22</xref>
</sup>, TFPI<sup>
<xref ref-type="bibr" rid="R23">23</xref>
</sup>, tPA, PAI-1<sup>
<xref ref-type="bibr" rid="R24">24</xref>
</sup> and FXIII<sup>
<xref ref-type="bibr" rid="R25">25</xref>
</sup> have already been reported, most of the studies were focused particularly on severe COVID-19. However, it is still unclear particularly when these key platelet activation markers and components of the coagulation system dysregulated during the COVID-19 pathogenesis and how they correlate with the progression of disease severity.</p>
<p id="P9">Here we report increase levels of plasma P-selectin and CD40 ligand (sCD40L) in the early moderate stage and the levels decline with the progression of the COVID-19 severity. Fibrinolysis pathway analysis revealed a similar pattern of PAI-1, a higher level in moderate vs. severe patients, and an elevated level of tPA only in severe COVID-19 cases. These findings provide strong evidence that platelet activation induces in the early stage of SARS-CoV-2 infection when COVID-19 patients present only moderate symptoms. COVID-19 severity advances with the activation of the TF pathway, the elevation of fibrinogen, and FXIII deficiency.</p>
</sec>
<sec id="S6" sec-type="subjects | methods">
<title>Patients and Methods</title>
<p id="P10">The study was conducted on COVID-19 patients, hospitalized in Rashid Hospital, Dubai between May-June 2020. SARS-CoV-2 infection was confirmed through the reverse transcription-polymerase chain reaction (RT-PCR). A total of 30 (15 moderate + 15 severe) hospitalized COVID-19 cases and 10 healthy controls (8 Males: 2 Females), age ranging from 25- 43 years, were included in the study. The family history and blood samples were collected from patients and healthy controls after getting written informed consent. The ethical approval to conduct the proposed studies was taken from the institutional ethical review boards of the University of Sharjah and Dubai Health Authority.</p>
<sec id="S7">
<title>Inclusion and exclusion criteria</title>
<p id="P11">The hospitalized moderate (without pneumonia or the requirement of intensive care) and severe COVID-19 patients (presented pneumonia and/or acute respiratory distress syndrome confirmed by Chest X-ray or CT scan and, required intensive care) were included in the study. Patients with a preexisting history of cardiovascular diseases including those with myocardial infarction, stroke, or deep vein thrombosis (DVT) were excluded from the study. Patients were also excluded if received thromboprophylaxis like low molecular weight heparin or other anti-coagulant. The healthy controls were recruited after taking the medical history and informed consent. Individuals on any type of medication or with a recent history of any medical conditions were excluded. Individuals without any current medications and/or a recent history of any disease were only included as healthy control.</p>
</sec>
<sec id="S8">
<title>Blood sample collection and plasma preparation</title>
<p id="P12">Blood samples from COVID-19 patients and healthy controls were collected in sodium citrate or EDTA-coated vials and processed quickly. The whole blood sample was centrifuged at 700<italic>g</italic> for 10 minutes and platelet-poor plasma was separated quickly and transferred to a fresh tube and stored at -80°C until further use.</p>
</sec>
<sec id="S9">
<title>Clinical laboratory investigation</title>
<p id="P13">Upon hospitalization, basic laboratory investigations including complete blood count (CBC), prothrombin time (PT), activated partial thromboplastin time (APTT), D-dimer, C reactive protein (CRP) were performed. PT, APTT, and D-dimer assays were performed using semi-automated coagulometer STAGO-STAR, and complete blood count (CBC) was measured under Beckman Coulter. The level of CRP was measured using Cobas b101 system and plasma ferritin level was measured using an immunoturbidimetric assay (Cobas 6000, Roche Diagnostics).</p>
</sec>
<sec id="S10">
<title>Flow cytometric detection of coagulation, thrombosis, and fibrinolysis markers</title>
<p id="P14">To detect the plasma levels of coagulation, thrombosis and fibrinolysis markers including FXI, anti-thrombin, prothrombin, fibrinogen, FXIII, P-selectin, sCD40L, plasminogen, tissue-plasminogen activator (tPA), plasminogen activator inhibitor-I (PAI-I) and D-Dimer, we performed multiplex bead-based assays using LegendPlex Human thrombosis (BioLegend #740906) and LegendPlex Human Fibrinolysis Panels (BioLegend #740761) following the manufacturer’s instruction. Briefly, diluted plasma samples from COVID-19 patients and healthy controls were used to measure the levels of soluble markers. Data were acquired under BD FACS Aria III using FACS Diva software and data analysis was done using Legendplex software (Biolegend, USA). All the samples were assessed in duplicate and the average was taken as a final reading.</p>
<sec id="S11">
<title>Quantification of human tissue factor pathway inhibitor</title>
<p id="P15">To quantify the tissue factor pathway inhibitor (TFPI) levels in the plasma samples of the COVID-19 patients and healthy controls, we performed a sandwich enzyme-linked immunosorbent assay (ELISA) using Human TFPI ELISA kit (Abcam# ab274392) according to the manufacturer’s instruction. All the samples were assessed in duplicate and the average was taken as a final reading.</p>
</sec>
</sec>
<sec id="S12">
<title>Statistics</title>
<p id="P16">Data group differences were evaluated for significance using unpaired <italic>t</italic>-test or one-way ANOVA followed by Tukey’s post-hoc test for multiple comparisons (Graph Pad Prism Software Inc., San Diego, CA). Data are expressed as mean ± SEM. For all tests, a <italic>P</italic>-value &lt;0.05 was considered for statistical significance.</p>
</sec>
</sec>
<sec id="S13" sec-type="results">
<title>Results</title>
<sec id="S14">
<title>Phenotypic and clinical presentation</title>
<p id="P17">The age range of recruited patients was between 32- 69 years (28 Males: 2 Females) and the majority of the cases were of Asian background. Laboratory investigations revealed a trend of prolonged PT irrespective of the COVID-19 severity. APTT was within the normal range in the moderate and a trend of prolongation was seen in the severe group. The platelet counts were in the normal range in both patient groups. As expected, the D-dimer level both in moderate and severe groups was higher than the normal range and the level was significantly higher in the severe vs. moderate COVID-19 patients. The laboratory investigations further suggested the induction of inflammatory reaction in COVID-19 cases in which an elevated level of plasma c-reactive protein (CRP) was identified in both moderate and severe cases. Moreover, increased inflammation was further indicated by a higher number of white blood cells (WBCs) including absolute lymphocyte counts (ALC), particularly in severe COVID-19 cases. The level of plasma creatinine was unchanged and profound induction of ferritin level was seen in both patient groups (<bold>Table</bold>).</p>
</sec>
<sec id="S15">
<title>SARS-CoV-2 induces the release of soluble platelet activation marker</title>
<p id="P18">Vascular inflammation often leads to endothelium damage and platelet activation through releasing numerous intermediate biologically active molecules.<sup>
<xref ref-type="bibr" rid="R26">26</xref>–<xref ref-type="bibr" rid="R28">28</xref>
</sup> Therefore, we sought to identify the stage of COVID-19 where the dysregulation of platelet activation markers occurs. In this series, the level of different soluble plasma markers including P-selectin and sCD40L were assessed in moderate and severe COVID-19 patients. Indeed, P-selectin was found to be markedly elevated in the moderate group which was significantly abolished in the severe COVID-19 cases (<xref ref-type="fig" rid="F1">Fig. 1A-B</xref>). Similarly, the level of sCD40L was found significantly elevated in the moderate COVID-19 cases and the level of sCD40L profoundly diminished with the advancement of severity (<xref ref-type="fig" rid="F1">Fig. 1C</xref>). These findings strongly suggest that SARS-CoV-2 triggers the release of P-selectin and sCD40L potentially from activated endothelial cells and induces platelet activation. The activated platelet further contributes to the elevated levels of P-selectin and sCD40L and thrombosis.</p>
</sec>
<sec id="S16">
<title>SARS-CoV-2 infection suppresses tissue factor pathway inhibitor, FXIII and induces fibrinogen</title>
<p id="P19">Accumulating data sets suggest that severe SARS-CoV-2 infection leads to coagulation dysfunction characterized by increased thrombin generation and elevated levels of D-Dimer <sup>
<xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R29">29</xref>
</sup>. Therefore, next, we assessed the potential dysregulation of intrinsic, extrinsic, and/or common coagulation pathways that might contribute to thrombin generation and ultimately platelet activation. We observed a comparable FIX level in moderate and severe cases vs. healthy controls (<xref ref-type="fig" rid="F2">Fig. 2B</xref>). However, extrinsic or TF pathway analysis revealed a trend of decline in plasma TF pathway inhibitor (TFPI) level in moderate patients which was significantly lower levels in the severe COVID-19 cases compared to healthy controls (<xref ref-type="fig" rid="F2">Fig. 2C</xref>). The assessment of the common coagulation pathway suggests unchanged plasma prothrombin and antithrombin levels in both moderate and severe cases (<xref ref-type="fig" rid="F2">Fig. 2A, D&amp;E</xref>). Interestingly, fibrinogen level was found markedly upregulated in moderate cases which further elevated with the progression of COVID-19 severity (<xref ref-type="fig" rid="F2">Fig. 2F</xref>). In stark contrast to fibrinogen level, a trend of lower FXIII level was observed in moderate cases, and the level further declined in severe COVID-19 (<xref ref-type="fig" rid="F2">Fig. 2G</xref>). These findings indicate that SARS-CoV-2 -infection dysregulates the extrinsic as well as common pathways by attenuating the plasma TFPI and FXIII levels, and by upregulating the fibrinogen level.</p>
</sec>
<sec id="S17">
<title>SARS-CoV-2 infection enhances tissue plasminogen activator and fibrinolysis</title>
<p id="P20">Aberrant fibrinolysis and elevated levels of D-dimer are commonly seen in COVID-19 patients particularly those who required intensive care. However, it is not clear whether elevated D-dimer is contributed due to dysregulation of fibrinolytic components during the early or late stage of COVID-19 pathogenesis. In this series, the key components of fibrinolysis pathways were assessed in moderate and severe patients. Interestingly, the PAI-1 level was profoundly elevated in the moderate patients and a comparatively lower level was observed in the severe patients (<xref ref-type="fig" rid="F3">Fig. 3A-B</xref>). In contrast, the level of tPA in the moderate cases was unchanged however, a significantly higher level was observed in the severe COVID-19 cases (<xref ref-type="fig" rid="F3">Fig. 3C</xref>). Moreover, aberrant fibrinolysis was confirmed in the recruited moderate and severe COVDI-19 cases by assessing the D-dimer levels through flow cytometry. Indeed, consistent with the tPA level in plasma, a trend of elevated D-dimer level was observed in the moderate cases and the level was found profoundly elevated in the severe COVID-19 (<xref ref-type="fig" rid="F3">Fig. 3D</xref>). Importantly, the plasminogen level was comparable in moderate and severe patients vs. healthy controls (<xref ref-type="fig" rid="F3">Fig. 3E</xref>). Overall, these findings strongly suggest that the increased level of PAI-1 in moderate cases likely causes increased resistance to fibrinolysis, which in turn, contributes to thrombosis. However, elevated levels of tPA, particularly in severe COVID-19 cases, promote hyperfibrinolysis and increase the level of D-dimer formation.</p>
</sec>
</sec>
<sec id="S18" sec-type="discussion">
<title>Discussion</title>
<p id="P21">Our findings show profoundly elevated levels of endothelial cell and platelet activation markers P-selectin and sCD40L in moderate cases and the levels were significantly abolished in critically ill patients. Moreover, attenuated levels of TFPI and FXIII, and a higher level of fibrinogen were observed particularly in the severe COVID-19. The level of PAI-1 was elevated in both the patient groups and increased tPA level was seen only in severe COVID-19 cases.</p>
<p id="P22">PT and APTT are the laboratory tools that predict the defective extrinsic and intrinsic coagulation pathways.<sup>
<xref ref-type="bibr" rid="R30">30</xref>
</sup> In contrast to our observations, a study has reported prolonged PT and APTT<sup>
<xref ref-type="bibr" rid="R31">31</xref>
</sup>, while others have shown shortened PT and APTT in severe vs. moderate patients.<sup>
<xref ref-type="bibr" rid="R32">32</xref>–<xref ref-type="bibr" rid="R33">33</xref>
</sup> Consistent with our findings, studies have also reported a comparable PT and APTT between moderate and severe patients.<sup>
<xref ref-type="bibr" rid="R34">34</xref>–<xref ref-type="bibr" rid="R35">35</xref>
</sup> Other coagulation parameters like D-dimer and fibrinogen are consistently reported to be elevated<sup>
<xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R35">35</xref>–<xref ref-type="bibr" rid="R36">36</xref>
</sup>, however, there are contradictory reports on thrombocytopenia in critical COVID-19 patients.<sup>
<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R35">35</xref>,<xref ref-type="bibr" rid="R37">37</xref>–<xref ref-type="bibr" rid="R38">38</xref>
</sup> Therefore, these initial diagnostic tools may not provide a clear clinical scenario of COVID-19 patients and a deeper investigation of coagulation pathway and molecular markers related to platelet activation might help in better clinical interpretation.</p>
<p id="P23">Soluble P-selectin, secreted by activated endothelial cells and platelets, not only activates platelets but also act as a key inflammatory mediator during viral infections including influenza <sup>
<xref ref-type="bibr" rid="R39">39</xref>–<xref ref-type="bibr" rid="R40">40</xref>
</sup> and SARS-CoV-2.<sup>
<xref ref-type="bibr" rid="R41">41</xref>
</sup> In our study, a higher level of plasma P-selectin in moderate COVID-19 cases, suggests that SARS-CoV-2 infection potentially triggers the release of P-selectin from endothelial cells which eventually contributes to inflammatory reaction and thrombotic complications, in turn, increases the severity of COVID-19. Consistent with P-selectin levels, sCD40L level was profoundly elevated in moderate COVID-19 patients. Platelet-derived sCD40L also provides vital signals to induce B cells activation and immunoglobulin secretion.<sup>
<xref ref-type="bibr" rid="R42">42</xref>
</sup> Another study highlights the influence of platelet- T-cell interactions during SARS-CoV-2 infections by modulating cytokine IL-17 and IFN-γ production.<sup>
<xref ref-type="bibr" rid="R43">43</xref>–<xref ref-type="bibr" rid="R44">44</xref>
</sup> Moreover, platelet- T cell interaction is clinically relevant as sCD40L was reported to enhance CD8+ T cell activity.<sup>
<xref ref-type="bibr" rid="R45">45</xref>
</sup> sCD40L plays a larger role in shaping innate immune responses through its cognate receptor, CD40, which is expressed on neutrophils<sup>
<xref ref-type="bibr" rid="R46">46</xref>
</sup>, endothelial cells<sup>
<xref ref-type="bibr" rid="R47">47</xref>
</sup>, and platelets.<sup>
<xref ref-type="bibr" rid="R48">48</xref>
</sup> This suggests the possible interaction between platelet and neutrophil in moderate COVID-19 which likely plays a role in disease severity. The platelet-neutrophil interaction was also previously reported in various other pathological conditions.<sup>
<xref ref-type="bibr" rid="R46">46</xref>
</sup> Such interactions in COVID-19 may lead to platelet-mediated neutrophil activation through sCD40L. Moreover, an increased level of sCD40L was found to be associated with plasma CRP level and platelet-monocytes interaction.<sup>
<xref ref-type="bibr" rid="R49">49</xref>
</sup> These studies signify the contribution of sCD40L in the SARS-CoV-2 -induced pathogenesis.</p>
<p id="P24">A trend of lower plasma TFPI levels was observed in the moderate cases and the levels further decreased in the severe COVID-19. The lower level of TFPI particularly in severe patients is likely insufficient to inhibit the procoagulant response which is induced by SARS-CoV-2 -mediated endothelial dysfunction. TFPI deficiency prompts thrombin generation via TF pathway and FX activation that ultimately induces platelet activation (<xref ref-type="fig" rid="F4">Fig. 4</xref>). In contrast to our findings, a recent study reported a higher level of TFPI in severe COVID-19 patients which was likely contributed due to heparin-induced TFPI release from endothelial cells as, unlike to our recruited cohort, patients were treated with heparin.<sup>
<xref ref-type="bibr" rid="R23">23</xref>
</sup> Local TF-dependent coagulation pathway activation and concomitant inhibition of fibrinolysis as indicated by the increased level of PAI-1 particularly in moderate COVID-19 cases are clinical features of ARDS. Such coagulation activation leads to alveolar fibrin deposition which is a pathological feature of early-phase acute lung injury.<sup>
<xref ref-type="bibr" rid="R50">50</xref>
</sup> It is evidenced that recombinant TFPI (recTFPI) has antithrombotic effects in a variety of <italic>ex vivo</italic> and <italic>in vivo</italic> experimental models <sup>
<xref ref-type="bibr" rid="R51">51</xref>
</sup>. Pre-clinical studies have evidenced that infusing a large dose of the recTFPI limits disseminated intravascular coagulation (DIC) induced by TF.<sup>
<xref ref-type="bibr" rid="R52">52</xref>–<xref ref-type="bibr" rid="R53">53</xref>
</sup>
</p>
<p id="P25">Our studies revealed a significantly decreased level of FXIII in the severe COVID-19 cases. Emerging pieces of evidence suggest that FXIII crosslink fibrin and promote thrombus stability during platelet accumulation and thrombosis.<sup>
<xref ref-type="bibr" rid="R54">54</xref>
</sup> Studies employing a ferric chloride-induced venous thrombosis model have shown an increased thrombus embolization in FXIII deficient mice.<sup>
<xref ref-type="bibr" rid="R55">55</xref>
</sup> Interestingly, FXIII supplementation stabilizes deep vein thrombi in mice and limits pulmonary embolism.<sup>
<xref ref-type="bibr" rid="R56">56</xref>
</sup> These findings suggest that acquired FXIII deficiency in the severe COVID-19 patients probably causes thrombus instability and embolization. Observed fibrinogen induction in the COVID-19 probably resulted due, partly, to the enhanced inflammatory reaction. It is also evident that fibrinogen and FXIII interact during thrombogenesis to activate FXIII and facilitate the delivery of FXIII to the growing thrombus.<sup>
<xref ref-type="bibr" rid="R54">54</xref>
</sup> A recent report suggests that FXIII plays a critical role in extravascular fibrinogen crosslinking.<sup>
<xref ref-type="bibr" rid="R57">57</xref>
</sup> Therefore, further investigation is required to establish if there is any direct correlation between enhanced fibrinogen and decreased FXIII levels in the severe COVID-19.</p>
<p id="P26">Aberrant fibrinolysis in COVID-19 patients is consistently reported by multiple studies.<sup>
<xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R37">37</xref>,<xref ref-type="bibr" rid="R58">58</xref>–<xref ref-type="bibr" rid="R59">59</xref>
</sup> The induction of PAI-1 observed in our COVID-19 patients indicates resistance to thrombus dissolution, at a higher level in the moderate stage which potentially promotes thrombosis. Moreover, elevated levels of tPA particularly in severe COVID-19 indicate the induction of hyperfibrinolysis. The findings are well-correlated with the significantly elevated level of D-dimer in the severe but not in moderate patients. Similar to our finding, recent studies also reported an elevated level of PIA-1 and tPA in hospitalized COVID-19 patients.<sup>
<xref ref-type="bibr" rid="R24">24</xref>,<xref ref-type="bibr" rid="R60">60</xref>
</sup> The study reported that an extremely elevated level of tPA was significantly associated with higher mortality.<sup>
<xref ref-type="bibr" rid="R24">24</xref>
</sup> The higher level of tPA is consistent with our findings where we have observed a higher level of tPA in the cohort of critically ill COVID-19 patients.</p>
<p id="P27">In conclusion, here we report the induction of platelet activation markers in the moderate stage of COVID-19, and the levels markedly declined with the progression of disease severity. A lower level of plasma TFPI in severe COVID-19 indicates the activation of the TF pathway. We show that the attenuated FXIII level was inversely correlated with the level of fibrinogen as COVID-19 severity progressed. The induction of PAI-1 in the moderate stage of the disease due, partly, to endothelial dysfunction and, tPA and D-dimer in severe conditions suggest a switch of fibrinolysis process with the progression of COVID-19 severity. These findings from moderate and severe disease stages would help design a better thromboprophylaxis strategy to minimize the thromboembolism and severity of COVID-19.</p>
</sec>
</body>
<back>
<ack id="S19">
<title>Acknowledgment</title>
<p>The work was supported by COVID-19 (CoV-0302), Targeted (1801090144-P), and Competitive (1901090162-P) research grants from the University of Sharjah to Firdos Ahmad. This work was also supported by the Cardiovascular Research Group at the University of Sharjah.</p>
</ack>
<fn-group>
<fn id="FN1" fn-type="conflict">
<p id="P28">
<bold>Conflict-of-interest:</bold> Declared none</p>
</fn>
<fn id="FN2" fn-type="con">
<p id="P29">
<bold>Author contribution:</bold> AOA, AMY, and MNJ performed experiments and collected data, AWA, ME, FA helped with sample and clinical data collection, MK and RH performed data interpretation and helped in manuscript writing, and FA design study, acquired funding, supervised the project, performed data analysis and interpretation, wrote and revised the manuscript.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giacomelli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pezzati</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Conti</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>
<article-title>Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study</article-title>
<source>Clin Infect Dis</source>
<year>2020</year>
<volume>71</volume>
<issue>15</issue>
<fpage>889</fpage>
<lpage>890</lpage>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guan</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>ZY</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Clinical Characteristics of Coronavirus Disease 2019 in China</article-title>
<source>N Engl J Med</source>
<year>2020</year>
<volume>382</volume>
<issue>18</issue>
<fpage>1708</fpage>
<lpage>1720</lpage>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klok</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Kruip</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van der Meer</surname>
<given-names>NJM</given-names>
</name>
<etal/>
</person-group>
<article-title>Incidence of thrombotic complications in critically ill ICU patients with COVID-19</article-title>
<source>Thromb Res</source>
<year>2020</year>
<volume>191</volume>
<fpage>145</fpage>
<lpage>147</lpage>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Thachil</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Iba</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Coagulation abnormalities and thrombosis in patients with COVID-19</article-title>
<source>Lancet Haematol</source>
<year>2020</year>
<volume>7</volume>
<issue>7</issue>
<fpage>e438</fpage>
<lpage>e440</lpage>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akhmerov</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Marban</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>COVID-19 and the Heart</article-title>
<source>Circ Res</source>
<year>2020</year>
<volume>126</volume>
<issue>10</issue>
<fpage>1443</fpage>
<lpage>1455</lpage>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia</article-title>
<source>J Thromb Haemost</source>
<year>2020</year>
<volume>18</volume>
<issue>4</issue>
<fpage>844</fpage>
<lpage>847</lpage>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liao</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study</article-title>
<source>Lancet Haematol</source>
<year>2020</year>
<volume>7</volume>
<issue>9</issue>
<fpage>e671</fpage>
<lpage>e678</lpage>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>IL (Interleukin)-6 Contributes to Deep Vein Thrombosis and Is Negatively Regulated by miR-338-5p</article-title>
<source>Arterioscler Thromb Vasc Biol</source>
<year>2020</year>
<volume>40</volume>
<issue>2</issue>
<fpage>323</fpage>
<lpage>334</lpage>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China</article-title>
<source>JAMA</source>
<year>2020</year>
<volume>323</volume>
<issue>11</issue>
<fpage>1061</fpage>
<lpage>1069</lpage>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmad</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kannan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ansari</surname>
<given-names>AW</given-names>
</name>
</person-group>
<article-title>Role of SARS-CoV-2 -induced cytokines and growth factors in coagulopathy and thromboembolism</article-title>
<source>Cytokine Growth Factor Rev</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goshua</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pine</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Meizlish</surname>
<given-names>ML</given-names>
</name>
<etal/>
</person-group>
<article-title>Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study</article-title>
<source>Lancet Haematol</source>
<year>2020</year>
<volume>7</volume>
<issue>8</issue>
<fpage>e575</fpage>
<lpage>e582</lpage>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Middleton</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Weyrich</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>Platelets in Pulmonary Immune Responses and Inflammatory Lung Diseases</article-title>
<source>Physiol Rev</source>
<year>2016</year>
<volume>96</volume>
<issue>4</issue>
<fpage>1211</fpage>
<lpage>1259</lpage>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girard</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Novotny</surname>
<given-names>WF</given-names>
</name>
<etal/>
</person-group>
<article-title>Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor</article-title>
<source>Nature</source>
<year>1989</year>
<volume>338</volume>
<issue>6215</issue>
<fpage>518</fpage>
<lpage>520</lpage>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wood</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Bunce</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Maroney</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Tracy</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Camire</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Mast</surname>
<given-names>AE</given-names>
</name>
</person-group>
<article-title>Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>2013</year>
<volume>110</volume>
<issue>44</issue>
<fpage>17838</fpage>
<lpage>17843</lpage>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mehta</surname>
<given-names>P</given-names>
</name>
<name>
<surname>McAuley</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sanchez</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tattersall</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Manson</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>COVID-19: consider cytokine storm syndromes and immunosuppression</article-title>
<source>Lancet</source>
<year>2020</year>
<volume>395</volume>
<issue>10229</issue>
<fpage>1033</fpage>
<lpage>1034</lpage>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Libby</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>DI</given-names>
</name>
</person-group>
<article-title>Inflammation and thrombosis: the clot thickens</article-title>
<source>Circulation</source>
<year>2001</year>
<volume>103</volume>
<issue>13</issue>
<fpage>1718</fpage>
<lpage>1720</lpage>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hottz</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Bozza</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Bozza</surname>
<given-names>PT</given-names>
</name>
</person-group>
<article-title>Platelets in Immune Response to Virus and Immunopathology of Viral Infections</article-title>
<source>Front Med (Lausanne)</source>
<year>2018</year>
<volume>5</volume>
<fpage>121</fpage>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raffetto</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Khalil</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Mechanisms of varicose vein formation: valve dysfunction and wall dilation</article-title>
<source>Phlebology</source>
<year>2008</year>
<volume>23</volume>
<issue>2</issue>
<fpage>85</fpage>
<lpage>98</lpage>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicholls</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Poon</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KC</given-names>
</name>
<etal/>
</person-group>
<article-title>Lung pathology of fatal severe acute respiratory syndrome</article-title>
<source>Lancet</source>
<year>2003</year>
<volume>361</volume>
<issue>9371</issue>
<fpage>1773</fpage>
<lpage>1778</lpage>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gralinski</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Bankhead</surname>
<given-names>A</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Jeng</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury</article-title>
<source>mBio</source>
<year>2013</year>
<volume>4</volume>
<issue>4</issue>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gralinski</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Baric</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Molecular pathology of emerging coronavirus infections</article-title>
<source>J Pathol</source>
<year>2015</year>
<volume>235</volume>
<issue>2</issue>
<fpage>185</fpage>
<lpage>195</lpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Biasi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Meschiari</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gibellini</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia</article-title>
<source>Nat Commun</source>
<year>2020</year>
<volume>11</volume>
<issue>1</issue>
<elocation-id>3434</elocation-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>White</surname>
<given-names>D</given-names>
</name>
<name>
<surname>MacDonald</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>Evaluation of COVID-19 coagulopathy; laboratory characterization using thrombin generation and nonconventional haemostasis assays</article-title>
<source>Int J Lab Hematol</source>
<year>2021</year>
<volume>43</volume>
<issue>1</issue>
<fpage>123</fpage>
<lpage>130</lpage>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zuo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Warnock</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Harbaugh</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients</article-title>
<source>Sci Rep</source>
<year>2021</year>
<volume>11</volume>
<issue>1</issue>
<elocation-id>1580</elocation-id>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>von Meijenfeldt</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Havervall</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Adelmeijer</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>COVID-19 is Associated with an Acquired Factor XIII Deficiency</article-title>
<source>Thromb Haemost</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kannan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Saxena</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Platelet activation markers in evaluation of thrombotic risk factors in various clinical settings</article-title>
<source>Blood Rev</source>
<year>2019</year>
<volume>37</volume>
<elocation-id>100583</elocation-id>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wagner</surname>
<given-names>DD</given-names>
</name>
</person-group>
<article-title>New links between inflammation and thrombosis</article-title>
<source>Arterioscler Thromb Vasc Biol</source>
<year>2005</year>
<volume>25</volume>
<issue>7</issue>
<fpage>1321</fpage>
<lpage>1324</lpage>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aloui</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Prigent</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sut</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>The signaling role of CD40 ligand in platelet biology and in platelet component transfusion</article-title>
<source>Int J Mol Sci</source>
<year>2014</year>
<volume>15</volume>
<issue>12</issue>
<fpage>22342</fpage>
<lpage>22364</lpage>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campello</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bulato</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Spiezia</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Thrombin generation in patients with COVID-19 with and without thromboprophylaxis</article-title>
<source>Clin Chem Lab Med</source>
<year>2021</year>
<volume>59</volume>
<issue>7</issue>
<fpage>1323</fpage>
<lpage>1330</lpage>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tripodi</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Thrombin Generation Assay and Its Application in the Clinical Laboratory</article-title>
<source>Clin Chem</source>
<year>2016</year>
<volume>62</volume>
<issue>5</issue>
<fpage>699</fpage>
<lpage>707</lpage>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China</article-title>
<source>Infection</source>
<year>2020</year>
<volume>48</volume>
<issue>4</issue>
<fpage>543</fpage>
<lpage>551</lpage>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spyropoulos</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Ageno</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>
<article-title>Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19</article-title>
<source>J Thromb Haemost</source>
<year>2020</year>
<volume>18</volume>
<issue>8</issue>
<fpage>1859</fpage>
<lpage>1865</lpage>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19</article-title>
<source>J Med Virol</source>
<year>2020</year>
<volume>92</volume>
<issue>7</issue>
<fpage>791</fpage>
<lpage>796</lpage>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>COVID-19 and coagulation dysfunction in adults: A systematic review and meta-analysis</article-title>
<source>J Med Virol</source>
<year>2021</year>
<volume>93</volume>
<issue>2</issue>
<fpage>934</fpage>
<lpage>944</lpage>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Samkari</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Karp Leaf</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Dzik</surname>
<given-names>WH</given-names>
</name>
<etal/>
</person-group>
<article-title>COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection</article-title>
<source>Blood</source>
<year>2020</year>
<volume>136</volume>
<issue>4</issue>
<fpage>489</fpage>
<lpage>500</lpage>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Panigada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bottino</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tagliabue</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>
<article-title>Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis</article-title>
<source>J Thromb Haemost</source>
<year>2020</year>
<volume>18</volume>
<issue>7</issue>
<fpage>1738</fpage>
<lpage>1742</lpage>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leentjens</surname>
<given-names>J</given-names>
</name>
<name>
<surname>van Haaps</surname>
<given-names>TF</given-names>
</name>
<name>
<surname>Wessels</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Schutgens</surname>
<given-names>REG</given-names>
</name>
<name>
<surname>Middeldorp</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year</article-title>
<source>Lancet Haematol</source>
<year>2021</year>
<elocation-id>S2352-3026(21):00105-00108</elocation-id>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Connors</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>COVID-19 and its implications for thrombosis and anticoagulation</article-title>
<source>Blood</source>
<year>2020</year>
<volume>135</volume>
<issue>23</issue>
<fpage>2033</fpage>
<lpage>2040</lpage>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koupenova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vitseva</surname>
<given-names>O</given-names>
</name>
<name>
<surname>MacKay</surname>
<given-names>CR</given-names>
</name>
<etal/>
</person-group>
<article-title>Platelet-TLR7 mediates host survival and platelet count during viral infection in the absence of platelet-dependent thrombosis</article-title>
<source>Blood</source>
<year>2014</year>
<volume>124</volume>
<issue>5</issue>
<fpage>791</fpage>
<lpage>802</lpage>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le</surname>
<given-names>VB</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Boergeling</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Platelet activation and aggregation promote lung inflammation and influenza virus pathogenesis</article-title>
<source>Am J Respir Crit Care Med</source>
<year>2015</year>
<volume>191</volume>
<issue>7</issue>
<fpage>804</fpage>
<lpage>819</lpage>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bongiovanni</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Klug</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lazareva</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotype</article-title>
<source>Cell Death Dis</source>
<year>2021</year>
<volume>12</volume>
<issue>1</issue>
<fpage>50</fpage>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elzey</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Sinn</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Nieswandt</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Waldschmidt</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Ratliff</surname>
<given-names>TL</given-names>
</name>
</person-group>
<article-title>Cooperation between platelet-derived CD154 and CD4+ T cells for enhanced germinal center formation</article-title>
<source>J Leukoc Biol</source>
<year>2005</year>
<volume>78</volume>
<issue>1</issue>
<fpage>80</fpage>
<lpage>84</lpage>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starossom</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Veremeyko</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yung</surname>
<given-names>AW</given-names>
</name>
<etal/>
</person-group>
<article-title>Platelets Play Differential Role During the Initiation and Progression of Autoimmune Neuroinflammation</article-title>
<source>Circ Res</source>
<year>2015</year>
<volume>117</volume>
<issue>9</issue>
<fpage>779</fpage>
<lpage>792</lpage>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zamora</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Canto</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Nieto</surname>
<given-names>JC</given-names>
</name>
<etal/>
</person-group>
<article-title>Functional consequences of platelet binding to T lymphocytes in inflammation</article-title>
<source>J Leukoc Biol</source>
<year>2013</year>
<volume>94</volume>
<issue>3</issue>
<fpage>521</fpage>
<lpage>529</lpage>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elzey</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>NW</given-names>
</name>
<name>
<surname>Crist</surname>
<given-names>SA</given-names>
</name>
<etal/>
</person-group>
<article-title>Platelet-derived CD154 enables T-cell priming and protection against Listeria monocytogenes challenge</article-title>
<source>Blood</source>
<year>2008</year>
<volume>111</volume>
<issue>7</issue>
<fpage>3684</fpage>
<lpage>3691</lpage>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Kelher</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Heal</surname>
<given-names>JM</given-names>
</name>
<etal/>
</person-group>
<article-title>Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury</article-title>
<source>Blood</source>
<year>2006</year>
<volume>108</volume>
<issue>7</issue>
<fpage>2455</fpage>
<lpage>2462</lpage>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henn</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Slupsky</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Grafe</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells</article-title>
<source>Nature</source>
<year>1998</year>
<volume>391</volume>
<issue>6667</issue>
<fpage>591</fpage>
<lpage>594</lpage>
</element-citation>
</ref>
<ref id="R48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inwald</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>McDowall</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Callard</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>NJ</given-names>
</name>
</person-group>
<article-title>CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation</article-title>
<source>Circ Res</source>
<year>2003</year>
<volume>92</volume>
<issue>9</issue>
<fpage>1041</fpage>
<lpage>1048</lpage>
</element-citation>
</ref>
<ref id="R49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harding</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Sommerfield</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Sarma</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus</article-title>
<source>Atherosclerosis</source>
<year>2004</year>
<volume>176</volume>
<issue>2</issue>
<fpage>321</fpage>
<lpage>325</lpage>
</element-citation>
</ref>
<ref id="R50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sebag</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Bastarache</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Ware</surname>
<given-names>LB</given-names>
</name>
</person-group>
<article-title>Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome</article-title>
<source>Curr Pharm Biotechnol</source>
<year>2011</year>
<volume>12</volume>
<issue>9</issue>
<fpage>1481</fpage>
<lpage>1496</lpage>
</element-citation>
</ref>
<ref id="R51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindahl</surname>
<given-names>AK</given-names>
</name>
</person-group>
<article-title>Tissue factor pathway inhibitor: from unknown coagulation inhibitor to major antithrombotic principle</article-title>
<source>Cardiovasc Res</source>
<year>1997</year>
<volume>33</volume>
<issue>2</issue>
<fpage>286</fpage>
<lpage>291</lpage>
</element-citation>
</ref>
<ref id="R52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Day</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Hoffman</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Palmier</surname>
<given-names>MO</given-names>
</name>
<etal/>
</person-group>
<article-title>Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit</article-title>
<source>Blood</source>
<year>1990</year>
<volume>76</volume>
<issue>8</issue>
<fpage>1538</fpage>
<lpage>1545</lpage>
</element-citation>
</ref>
<ref id="R53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Creasey</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Feigen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wun</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>FB</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Hinshaw</surname>
<given-names>LB</given-names>
</name>
</person-group>
<article-title>Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock</article-title>
<source>J Clin Invest</source>
<year>1993</year>
<volume>91</volume>
<issue>6</issue>
<fpage>2850</fpage>
<lpage>2860</lpage>
</element-citation>
</ref>
<ref id="R54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Byrnes</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Wolberg</surname>
<given-names>AS</given-names>
</name>
</person-group>
<article-title>Newly-Recognized Roles of Factor XIII in Thrombosis</article-title>
<source>Semin Thromb Hemost</source>
<year>2016</year>
<volume>42</volume>
<issue>4</issue>
<fpage>445</fpage>
<lpage>454</lpage>
</element-citation>
</ref>
<ref id="R55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shaya</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Saldanha</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Vaezzadeh</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>PL</given-names>
</name>
</person-group>
<article-title>Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism</article-title>
<source>J Thromb Haemost</source>
<year>2016</year>
<volume>14</volume>
<issue>1</issue>
<fpage>143</fpage>
<lpage>152</lpage>
</element-citation>
</ref>
<ref id="R56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shaya</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Gani</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Weitz</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>PY</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>PL</given-names>
</name>
</person-group>
<article-title>Factor XIII Prevents Pulmonary Emboli in Mice by Stabilizing Deep Vein Thrombi</article-title>
<source>Thromb Haemost</source>
<year>2019</year>
<volume>119</volume>
<issue>6</issue>
<fpage>992</fpage>
<lpage>999</lpage>
</element-citation>
</ref>
<ref id="R57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poole</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Kopec</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Groeneveld</surname>
<given-names>DJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Factor XIII cross-links fibrin(ogen) independent of fibrin polymerization in experimental acute liver injury</article-title>
<source>Blood</source>
<year>2021</year>
<volume>137</volume>
<issue>18</issue>
<fpage>2520</fpage>
<lpage>2531</lpage>
</element-citation>
</ref>
<ref id="R58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopes</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>de Barros</surname>
<given-names>ESPGM</given-names>
</name>
<name>
<surname>Furtado</surname>
<given-names>RHM</given-names>
</name>
<etal/>
</person-group>
<article-title>Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial</article-title>
<source>Lancet</source>
<year>2021</year>
<elocation-id>S0140-6736(21):01203-01204</elocation-id>
</element-citation>
</ref>
<ref id="R59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boscolo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Spiezia</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Correale</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Different Hypercoagulable Profiles in Patients with COVID-19 Admitted to the Internal Medicine Ward and the Intensive Care Unit</article-title>
<source>Thromb Haemost</source>
<year>2020</year>
<volume>120</volume>
<issue>10</issue>
<fpage>1474</fpage>
<lpage>1477</lpage>
</element-citation>
</ref>
<ref id="R60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hammer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Haberle</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schlensak</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Severe SARS-CoV-2 Infection Inhibits Fibrinolysis Leading to Changes in Viscoelastic Properties of Blood Clot: A Descriptive Study of Fibrinolysis in COVID-19</article-title>
<source>Thromb Haemost</source>
<year>2021</year>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<title>Plasma prothrombotic markers level increase at the moderate stage of COVID-19.</title>
<p>(<bold>A</bold>) Representative flow cytometry scatter dot plots show the levels of P-selectin and soluble CD40 ligand (sCD40L) in moderate and severe COVID-19 patients vs. healthy controls. Scatter dot plots show significantly elevated levels of (<bold>B</bold>) P-selectin and (<bold>C</bold>) sCD40L in moderate patients and significantly lower levels in the severe vs. moderate COVID-19 patients. *, p&lt;0.05; ***, p&lt;0.0005; ****, p&lt;0.0001.</p>
</caption>
<graphic xlink:href="EMS134146-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<title>SARS-CoV-2 suppresses TFPI and factor XIII, and induces fibrinogen levels.</title>
<p>(<bold>A</bold>) Representative scatter dot plots from flow cytometry-based multiplex assay shows the levels of plasma factor XIII (FXIII), fibrinogen, and prothrombin in COVID-19 patients. (<bold>B</bold>) Analysis shows an unchanged FIX level in COVID-19 cases. (<bold>C</bold>) Scatter dot plot from ELISA shows a significantly low level of tissue factor pathway inhibitor (TFPI) particularly in severe COVID-19 patients vs. healthy controls. Scatter dot plots from multiplex assay show comparable (<bold>D</bold>) prothrombin and (<bold>E</bold>) antithrombin levels, (<bold>F</bold>) significantly higher levels of fibrinogen, and (<bold>G</bold>) lower levels of FXIII in COVID-19 patients vs. healthy controls. *, p&lt;0.05; **, p&lt;0.005; ****, p&lt;0.0001.</p>
</caption>
<graphic xlink:href="EMS134146-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<title>Defective fibrinolysis in COVID-19.</title>
<p>(<bold>A</bold>) Representative scatter dot plots from multiplex assay show a higher level of D-dimer, plasminogen activator inhibitor-1 (PAI-1), and tissue plasminogen activator (tPA) in COVID-19 patients. Scatter dot plots show a higher level of (<bold>B</bold>) PAI-1 both in moderate and severe, (<bold>C</bold>) tPA in severe, (<bold>D</bold>) D-dimer particularly in severe COVID-19 vs. healthy controls, and (<bold>E</bold>) comparable plasminogen level between controls and COVID-19 patients. *, p&lt;0.05; **, p&lt;0.005; ****, p&lt;0.0001.</p>
</caption>
<graphic xlink:href="EMS134146-f003"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<title>Diagram illustrating the SARS-CoV-2 -mediated induction of plasma CD40L and P-selectin levels, and suppression of tissue factor pathway and FXIII.</title>
<p>SARS-CoV-2 -mediated endothelium damage potentially contributes to the elevated level of plasma CD40L (sCD40L) and P-selectin which induces platelet activation. The activated platelet further releases P-selectin and sCD40L and provides positive feedback to platelet plug formation and platelet-mediated thrombin generation. An attenuated level of TFPI activates the tissue factor pathway which likely boosts thrombin level and enhances platelet activation. The elevated level of fibrinogen in COVID-19 patients likely provides the required fibrin however, a decreased level of FXIII indicates the defective fibrin polymerization which potentially results in unstable thrombi formation and embolization. Moreover, an elevated level of PAI-1 prevents fibrinolysis in moderate COVID-19, however, an increased level of tPA in severe COVID-19 likely induces hyperfibrinolysis in turn increased level of D-dimer formation. s<bold>CD40L</bold>; soluble CD40 ligand, <bold>TFPI</bold>; tissue factor pathway inhibitor, <bold>FXIII</bold>; factor XIII, <bold>PAI-1</bold>; plasminogen activator inhibitor-1, <bold>tPA</bold>; tissue plasminogen activator, <bold>+</bold>; positive feedback. Dotted lines; not known if direct or indirect regulation, Solid line; direct regulation.</p>
</caption>
<graphic xlink:href="EMS134146-f004"/>
</fig>
<table-wrap id="T1" position="float" orientation="portrait">
<label>Table 1</label>
<caption>
<p>Table shows different clinical parameters of included moderate and severe COVID-19 patients. <bold>ALC;</bold> absolute lymphocyte count, <bold>CRP;</bold> C-reactive protein, <bold>LDH;</bold> Lactate dehydrogenase, <bold>ALT;</bold> Alanine transaminase, <bold>PT;</bold> Prothrombin time, <bold>APTT;</bold> Activated partial thromboplastin time; <bold>NA</bold>, not available. The normal ranges are provided in the bracket. *, p&lt;0.05; ***, p&lt;0.0005 for comparison between the moderate and severe groups.</p>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="center" valign="middle" style="background-color:#F2DCDB">S. No</th>
<th align="center" valign="middle" style="background-color:#F2DCDB">Code</th>
<th align="center" valign="middle" style="background-color:#F2DCDB">Age Year</th>
<th align="center" valign="middle" style="background-color:#F2DCDB">Sex</th>
<th align="center" valign="middle" style="background-color:#F2DCDB">Weight Kg</th>
<th align="center" valign="middle" style="background-color:#F2DCDB">Height cm</th>
<th align="center" valign="middle" style="background-color:#F2DCDB">Severity</th>
<th align="center" valign="middle" style="background-color:#F2DCDB">ALC (0.8-5.0) x10<sup>9</sup>/L*</th>
<th align="center" valign="middle" style="background-color:#F2DCDB">CRP (&lt;10) μg/mL</th>
<th align="center" valign="middle" style="background-color:#F2DCDB">Creatinine (0.7 to 1.3) mg/dL</th>
<th align="center" valign="middle" style="background-color:#F2DCDB">Ferritin (24 to 336) ng/mL</th>
<th align="center" valign="middle" style="background-color:#F2DCDB">LDH (140-280) IU/L</th>
<th align="center" valign="middle" style="background-color:#F2DCDB">ALT (29-35) IU/L</th>
<th align="center" valign="middle" style="background-color:#F2DCDB">D-Dimer (&lt;0.5) ng/mL*</th>
<th align="center" valign="middle" style="background-color:#F2DCDB">PT (11-13.5) Sec</th>
<th align="center" valign="middle" style="background-color:#F2DCDB">APTT (30-40) (Sec)</th>
<th align="center" valign="middle" style="background-color:#F2DCDB">Platelets (150-400) x10<sup>9</sup>/L</th>
<th align="center" valign="middle" style="background-color:#F2DCDB">WBC (4.5-11) (x10<sup>9</sup>/L) ***</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">13</td>
<td align="center" valign="middle">50</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">83</td>
<td align="center" valign="middle">177</td>
<td align="center" valign="middle">Moderate</td>
<td align="center" valign="middle">1.8</td>
<td align="center" valign="middle">3.3</td>
<td align="center" valign="middle">0.7</td>
<td align="center" valign="middle">391</td>
<td align="center" valign="middle">1719</td>
<td align="center" valign="middle">30</td>
<td align="center" valign="middle">1.7</td>
<td align="center" valign="middle">15.9</td>
<td align="center" valign="middle">31.9</td>
<td align="center" valign="middle">153</td>
<td align="center" valign="middle">4.5</td>
</tr>
<tr>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">14</td>
<td align="center" valign="middle">48</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">68</td>
<td align="center" valign="middle">167</td>
<td align="center" valign="middle">Moderate</td>
<td align="center" valign="middle">1.2</td>
<td align="center" valign="middle">204</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">2807</td>
<td align="center" valign="middle">1346</td>
<td align="center" valign="middle">45</td>
<td align="center" valign="middle">1.81</td>
<td align="center" valign="middle">13.6</td>
<td align="center" valign="middle">32</td>
<td align="center" valign="middle">349</td>
<td align="center" valign="middle">9</td>
</tr>
<tr>
<td align="center" valign="middle">3</td>
<td align="center" valign="middle">30</td>
<td align="center" valign="middle">36</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">72.5</td>
<td align="center" valign="middle">175.5</td>
<td align="center" valign="middle">Moderate</td>
<td align="center" valign="middle">0.2</td>
<td align="center" valign="middle">189.6</td>
<td align="center" valign="middle">1.8</td>
<td align="center" valign="middle">4917.8</td>
<td align="center" valign="middle">310</td>
<td align="center" valign="middle">40</td>
<td align="center" valign="middle">3.63</td>
<td align="center" valign="middle">19.6</td>
<td align="center" valign="middle">38.9</td>
<td align="center" valign="middle">187</td>
<td align="center" valign="middle">14</td>
</tr>
<tr>
<td align="center" valign="middle">4</td>
<td align="center" valign="middle">32</td>
<td align="center" valign="middle">49</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">84</td>
<td align="center" valign="middle">160</td>
<td align="center" valign="middle">Moderate</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">23.7</td>
<td align="center" valign="middle">0.8</td>
<td align="center" valign="middle">330.7</td>
<td align="center" valign="middle">280</td>
<td align="center" valign="middle">9</td>
<td align="center" valign="middle">1.48</td>
<td align="center" valign="middle">14.4</td>
<td align="center" valign="middle">37.9</td>
<td align="center" valign="middle">325</td>
<td align="center" valign="middle">7.5</td>
</tr>
<tr>
<td align="center" valign="middle">5</td>
<td align="center" valign="middle">42</td>
<td align="center" valign="middle">48</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">94</td>
<td align="center" valign="middle">180</td>
<td align="center" valign="middle">Moderate</td>
<td align="center" valign="middle">1.3</td>
<td align="center" valign="middle">100.4</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">1518.6</td>
<td align="center" valign="middle">950</td>
<td align="center" valign="middle">76</td>
<td align="center" valign="middle">1.49</td>
<td align="center" valign="middle">14</td>
<td align="center" valign="middle">38.6</td>
<td align="center" valign="middle">294</td>
<td align="center" valign="middle">6.4</td>
</tr>
<tr>
<td align="center" valign="middle">6</td>
<td align="center" valign="middle">39</td>
<td align="center" valign="middle">46</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">86</td>
<td align="center" valign="middle">165</td>
<td align="center" valign="middle">Moderate</td>
<td align="center" valign="middle">1.5</td>
<td align="center" valign="middle">2.7</td>
<td align="center" valign="middle">0.7</td>
<td align="center" valign="middle">234</td>
<td align="center" valign="middle">237</td>
<td align="center" valign="middle">26</td>
<td align="center" valign="middle">0.82</td>
<td align="center" valign="middle">13.1</td>
<td align="center" valign="middle">33.5</td>
<td align="center" valign="middle">127</td>
<td align="center" valign="middle">4.6</td>
</tr>
<tr>
<td align="center" valign="middle">7</td>
<td align="center" valign="middle">54</td>
<td align="center" valign="middle">67</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">67</td>
<td align="center" valign="middle">168</td>
<td align="center" valign="middle">Moderate</td>
<td align="center" valign="middle">0.9</td>
<td align="center" valign="middle">26.4</td>
<td align="center" valign="middle">0.9</td>
<td align="center" valign="middle">315</td>
<td align="center" valign="middle">336</td>
<td align="center" valign="middle">50</td>
<td align="center" valign="middle">1.98</td>
<td align="center" valign="middle">18.7</td>
<td align="center" valign="middle">48.4</td>
<td align="center" valign="middle">62</td>
<td align="center" valign="middle">12.3</td>
</tr>
<tr>
<td align="center" valign="middle">8</td>
<td align="center" valign="middle">59</td>
<td align="center" valign="middle">53</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">104</td>
<td align="center" valign="middle">194</td>
<td align="center" valign="middle">Moderate</td>
<td align="center" valign="middle">0.7</td>
<td align="center" valign="middle">0.6</td>
<td align="center" valign="middle">0.6</td>
<td align="center" valign="middle">536</td>
<td align="center" valign="middle">206</td>
<td align="center" valign="middle">21</td>
<td align="center" valign="middle">0.35</td>
<td align="center" valign="middle">13.8</td>
<td align="center" valign="middle">31</td>
<td align="center" valign="middle">233</td>
<td align="center" valign="middle">4.4</td>
</tr>
<tr>
<td align="center" valign="middle">9</td>
<td align="center" valign="middle">61</td>
<td align="center" valign="middle">42</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">180</td>
<td align="center" valign="middle">Moderate</td>
<td align="center" valign="middle">2.8</td>
<td align="center" valign="middle">0.3</td>
<td align="center" valign="middle">0.9</td>
<td align="center" valign="middle">216</td>
<td align="center" valign="middle">154</td>
<td align="center" valign="middle">39</td>
<td align="center" valign="middle">0.13</td>
<td align="center" valign="middle">15.3</td>
<td align="center" valign="middle">54.8</td>
<td align="center" valign="middle">231</td>
<td align="center" valign="middle">7.3</td>
</tr>
<tr>
<td align="center" valign="middle">10</td>
<td align="center" valign="middle">63</td>
<td align="center" valign="middle">42</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">107</td>
<td align="center" valign="middle">165</td>
<td align="center" valign="middle">Moderate</td>
<td align="center" valign="middle">2.9</td>
<td align="center" valign="middle">10.9</td>
<td align="center" valign="middle">0.9</td>
<td align="center" valign="middle">225</td>
<td align="center" valign="middle">241</td>
<td align="center" valign="middle">57</td>
<td align="center" valign="middle">0.34</td>
<td align="center" valign="middle">12.6</td>
<td align="center" valign="middle">37.7</td>
<td align="center" valign="middle">319</td>
<td align="center" valign="middle">13.2</td>
</tr>
<tr>
<td align="center" valign="middle">11</td>
<td align="center" valign="middle">210</td>
<td align="center" valign="middle">57</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">85</td>
<td align="center" valign="middle">180</td>
<td align="center" valign="middle">Moderate</td>
<td align="center" valign="middle">0.9</td>
<td align="center" valign="middle">58.6</td>
<td align="center" valign="middle">0.9</td>
<td align="center" valign="middle">363</td>
<td align="center" valign="middle">151</td>
<td align="center" valign="middle">44</td>
<td align="center" valign="middle">0.52</td>
<td align="center" valign="middle">16.9</td>
<td align="center" valign="middle">34.7</td>
<td align="center" valign="middle">207</td>
<td align="center" valign="middle">5.9</td>
</tr>
<tr>
<td align="center" valign="middle">12</td>
<td align="center" valign="middle">8</td>
<td align="center" valign="middle">32</td>
<td align="center" valign="middle">Female</td>
<td align="center" valign="middle">55</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">Moderate</td>
<td align="center" valign="middle">2.3</td>
<td align="center" valign="middle">212.2</td>
<td align="center" valign="middle">0.5</td>
<td align="center" valign="middle">4119</td>
<td align="center" valign="middle">518</td>
<td align="center" valign="middle">53</td>
<td align="center" valign="middle">1.13</td>
<td align="center" valign="middle">13.3</td>
<td align="center" valign="middle">38.4</td>
<td align="center" valign="middle">257</td>
<td align="center" valign="middle">9.3</td>
</tr>
<tr>
<td align="center" valign="middle">13</td>
<td align="center" valign="middle">9</td>
<td align="center" valign="middle">48</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">51.5</td>
<td align="center" valign="middle">162.5</td>
<td align="center" valign="middle">Moderate</td>
<td align="center" valign="middle">1.3</td>
<td align="center" valign="middle">9.5</td>
<td align="center" valign="middle">1.1</td>
<td align="center" valign="middle">210</td>
<td align="center" valign="middle">146</td>
<td align="center" valign="middle">24</td>
<td align="center" valign="middle">0.9</td>
<td align="center" valign="middle">14.4</td>
<td align="center" valign="middle">36.8</td>
<td align="center" valign="middle">347</td>
<td align="center" valign="middle">8.3</td>
</tr>
<tr>
<td align="center" valign="middle">14</td>
<td align="center" valign="middle">17</td>
<td align="center" valign="middle">49</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">98</td>
<td align="center" valign="middle">175</td>
<td align="center" valign="middle">Moderate</td>
<td align="center" valign="middle">1.3</td>
<td align="center" valign="middle">197</td>
<td align="center" valign="middle">0.6</td>
<td align="center" valign="middle">1594.90</td>
<td align="center" valign="middle">407</td>
<td align="center" valign="middle">57</td>
<td align="center" valign="middle">1.2</td>
<td align="center" valign="middle">16</td>
<td align="center" valign="middle">45.4</td>
<td align="center" valign="middle">255</td>
<td align="center" valign="middle">10</td>
</tr>
<tr>
<td align="center" valign="middle">15</td>
<td align="center" valign="middle">31</td>
<td align="center" valign="middle">54</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">100</td>
<td align="center" valign="middle">182</td>
<td align="center" valign="middle">Moderate</td>
<td align="center" valign="middle">1.1</td>
<td align="center" valign="middle">36.2</td>
<td align="center" valign="middle">2.6</td>
<td align="center" valign="middle">315.6</td>
<td align="center" valign="middle">191</td>
<td align="center" valign="middle">10</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">12.8</td>
<td align="center" valign="middle">40.8</td>
<td align="center" valign="middle">183</td>
<td align="center" valign="middle">4.5</td>
</tr>
<tr>
<td align="center" valign="middle">16</td>
<td align="center" valign="middle">71</td>
<td align="center" valign="middle">48</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">68</td>
<td align="center" valign="middle">161</td>
<td align="center" valign="middle">Severe</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">141.6</td>
<td align="center" valign="middle">0.3</td>
<td align="center" valign="middle">1235</td>
<td align="center" valign="middle">647</td>
<td align="center" valign="middle">11</td>
<td align="center" valign="middle">3.68</td>
<td align="center" valign="middle">14.9</td>
<td align="center" valign="middle">49.2</td>
<td align="center" valign="middle">292</td>
<td align="center" valign="middle">19.8</td>
</tr>
<tr>
<td align="center" valign="middle">17</td>
<td align="center" valign="middle">75</td>
<td align="center" valign="middle">38</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">60</td>
<td align="center" valign="middle">177</td>
<td align="center" valign="middle">Severe</td>
<td align="center" valign="middle">2.2</td>
<td align="center" valign="middle">81.3</td>
<td align="center" valign="middle">0.2</td>
<td align="center" valign="middle">814</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">7</td>
<td align="center" valign="middle">1.04</td>
<td align="center" valign="middle">15.4</td>
<td align="center" valign="middle">50.8</td>
<td align="center" valign="middle">432</td>
<td align="center" valign="middle">7.5</td>
</tr>
<tr>
<td align="center" valign="middle">18</td>
<td align="center" valign="middle">76</td>
<td align="center" valign="middle">57</td>
<td align="center" valign="middle">Female</td>
<td align="center" valign="middle">70</td>
<td align="center" valign="middle">161</td>
<td align="center" valign="middle">Severe</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">32</td>
<td align="center" valign="middle">0.3</td>
<td align="center" valign="middle">505</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">15</td>
<td align="center" valign="middle">2.67</td>
<td align="center" valign="middle">12.5</td>
<td align="center" valign="middle">44.6</td>
<td align="center" valign="middle">395</td>
<td align="center" valign="middle">8.7</td>
</tr>
<tr>
<td align="center" valign="middle">19</td>
<td align="center" valign="middle">78</td>
<td align="center" valign="middle">52</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">Severe</td>
<td align="center" valign="middle">6.5</td>
<td align="center" valign="middle">125.1</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">684.5</td>
<td align="center" valign="middle">413</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">0.9</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">331</td>
<td align="center" valign="middle">9.3</td>
</tr>
<tr>
<td align="center" valign="middle">20</td>
<td align="center" valign="middle">85</td>
<td align="center" valign="middle">65</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">82</td>
<td align="center" valign="middle">170</td>
<td align="center" valign="middle">Severe</td>
<td align="center" valign="middle">0.5</td>
<td align="center" valign="middle">503</td>
<td align="center" valign="middle">3</td>
<td align="center" valign="middle">351</td>
<td align="center" valign="middle">815</td>
<td align="center" valign="middle">99</td>
<td align="center" valign="middle">&gt;20</td>
<td align="center" valign="middle">17.4</td>
<td align="center" valign="middle">49.4</td>
<td align="center" valign="middle">120</td>
<td align="center" valign="middle">23.6</td>
</tr>
<tr>
<td align="center" valign="middle">21</td>
<td align="center" valign="middle">86</td>
<td align="center" valign="middle">50</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">Severe</td>
<td align="center" valign="middle">7</td>
<td align="center" valign="middle">148.2</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">975.5</td>
<td align="center" valign="middle">498</td>
<td align="center" valign="middle">28</td>
<td align="center" valign="middle">1.35</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">538</td>
<td align="center" valign="middle">24.7</td>
</tr>
<tr>
<td align="center" valign="middle">22</td>
<td align="center" valign="middle">87</td>
<td align="center" valign="middle">69</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">101</td>
<td align="center" valign="middle">173</td>
<td align="center" valign="middle">Severe</td>
<td align="center" valign="middle">1.1</td>
<td align="center" valign="middle">154</td>
<td align="center" valign="middle">2.2</td>
<td align="center" valign="middle">5147</td>
<td align="center" valign="middle">172</td>
<td align="center" valign="middle">11</td>
<td align="center" valign="middle">8.58</td>
<td align="center" valign="middle">18.5</td>
<td align="center" valign="middle">42.3</td>
<td align="center" valign="middle">167</td>
<td align="center" valign="middle">24.7</td>
</tr>
<tr>
<td align="center" valign="middle">23</td>
<td align="center" valign="middle">89</td>
<td align="center" valign="middle">59</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">80.5</td>
<td align="center" valign="middle">165</td>
<td align="center" valign="middle">Severe</td>
<td align="center" valign="middle">1.6</td>
<td align="center" valign="middle">65.9</td>
<td align="center" valign="middle">0.8</td>
<td align="center" valign="middle">1400</td>
<td align="center" valign="middle">317</td>
<td align="center" valign="middle">26</td>
<td align="center" valign="middle">0.86</td>
<td align="center" valign="middle">13.3</td>
<td align="center" valign="middle">56</td>
<td align="center" valign="middle">236</td>
<td align="center" valign="middle">11.3</td>
</tr>
<tr>
<td align="center" valign="middle">24</td>
<td align="center" valign="middle">91</td>
<td align="center" valign="middle">60</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">Severe</td>
<td align="center" valign="middle">9</td>
<td align="center" valign="middle">275.4</td>
<td align="center" valign="middle">1.7</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">576</td>
<td align="center" valign="middle">14</td>
<td align="center" valign="middle">2.6</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">343</td>
<td align="center" valign="middle">25.7</td>
</tr>
<tr>
<td align="center" valign="middle">25</td>
<td align="center" valign="middle">92</td>
<td align="center" valign="middle">57</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">84</td>
<td align="center" valign="middle">157</td>
<td align="center" valign="middle">Severe</td>
<td align="center" valign="middle">0.8</td>
<td align="center" valign="middle">34.7</td>
<td align="center" valign="middle">0.7</td>
<td align="center" valign="middle">2045</td>
<td align="center" valign="middle">781</td>
<td align="center" valign="middle">89</td>
<td align="center" valign="middle">0.98</td>
<td align="center" valign="middle">13.2</td>
<td align="center" valign="middle">33.7</td>
<td align="center" valign="middle">443</td>
<td align="center" valign="middle">18.5</td>
</tr>
<tr>
<td align="center" valign="middle">26</td>
<td align="center" valign="middle">94</td>
<td align="center" valign="middle">50</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">57</td>
<td align="center" valign="middle">165</td>
<td align="center" valign="middle">Severe</td>
<td align="center" valign="middle">0.7</td>
<td align="center" valign="middle">2.4</td>
<td align="center" valign="middle">0.9</td>
<td align="center" valign="middle">139.6</td>
<td align="center" valign="middle">327</td>
<td align="center" valign="middle">30</td>
<td align="center" valign="middle">1.18</td>
<td align="center" valign="middle">13.7</td>
<td align="center" valign="middle">36.3</td>
<td align="center" valign="middle">407</td>
<td align="center" valign="middle">21.8</td>
</tr>
<tr>
<td align="center" valign="middle">27</td>
<td align="center" valign="middle">95</td>
<td align="center" valign="middle">62</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">Severe</td>
<td align="center" valign="middle">8</td>
<td align="center" valign="middle">236.8</td>
<td align="center" valign="middle">1.2</td>
<td align="center" valign="middle">2994.5</td>
<td align="center" valign="middle">887</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">1.98</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">149</td>
<td align="center" valign="middle">15.5</td>
</tr>
<tr>
<td align="center" valign="middle">28</td>
<td align="center" valign="middle">96</td>
<td align="center" valign="middle">48</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">74</td>
<td align="center" valign="middle">165</td>
<td align="center" valign="middle">Severe</td>
<td align="center" valign="middle">0.9</td>
<td align="center" valign="middle">111</td>
<td align="center" valign="middle">1.1</td>
<td align="center" valign="middle">1389</td>
<td align="center" valign="middle">680</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">6</td>
<td align="center" valign="middle">14.3</td>
<td align="center" valign="middle">45.8</td>
<td align="center" valign="middle">171</td>
<td align="center" valign="middle">3.8</td>
</tr>
<tr>
<td align="center" valign="middle">29</td>
<td align="center" valign="middle">97</td>
<td align="center" valign="middle">41</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">Severe</td>
<td align="center" valign="middle">3.8</td>
<td align="center" valign="middle">95.9</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">396.5</td>
<td align="center" valign="middle">221</td>
<td align="center" valign="middle">56</td>
<td align="center" valign="middle">1.22</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">133</td>
<td align="center" valign="middle">12.1</td>
</tr>
<tr>
<td align="center" valign="middle">30</td>
<td align="center" valign="middle">98</td>
<td align="center" valign="middle">63</td>
<td align="center" valign="middle">Male</td>
<td align="center" valign="middle">58</td>
<td align="center" valign="middle">163</td>
<td align="center" valign="middle">Severe</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">17.1</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">862</td>
<td align="center" valign="middle">611</td>
<td align="center" valign="middle">148</td>
<td align="center" valign="middle">10.3</td>
<td align="center" valign="middle">16</td>
<td align="center" valign="middle">34.4</td>
<td align="center" valign="middle">370</td>
<td align="center" valign="middle">25.2</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
